<DOC>
	<DOCNO>NCT00228371</DOCNO>
	<brief_summary>The aim study evaluate effectiveness safety deep brain stimulation drug resistant epilepsy . This double blind , control randomized clinical trial two cross-over group four phase . Phase 1 : base line , open phase consist follow-up patient standard treatment . Phase 2 : Randomisation , lead implantation , follow 3 month wash period stimulator switch OFF . Phase 3 : cross-over , double blind phase : 3 month stimulator switch ON OFF depend randomization allocation , follow 3 month stimulator switch opposite position . The placebo consist turn OFF stimulator . Phase 4 : open phase , one year follow-up patient stimulator switch ON .</brief_summary>
	<brief_title>STIMEP : Assessment Subthalamic Nucleus Stimulation Drug Resistant Epilepsy</brief_title>
	<detailed_description>The experimental work perform 15 year several research team show animal model epilepsy , several circuit basal ganglion involve control epilepsy seizure . The existence circuit lead possibility therapeutic application particular deep brain stimulation . Preliminary result ( Benabid et al , 2002 ) ( Chabardes et al , 2002 ) suggest neuromodulation basal ganglia particular subthalamic nucleus substantia nigra par reticulata could therapeutic effect patient drug resistant epilepsy possibility resection surgery . This double blind , control randomized clinical trial two cross-over group four phase . Phase 1 : base line , open phase consist follow-up patient standard treatment . Phase 2 : Randomisation , lead implantation , follow 3 month wash period stimulator switch OFF . Phase 3 : cross-over , double blind phase : 3 month stimulator switch ON OFF depend randomization allocation , follow 3 month stimulator switch opposite position . Phase 4 : open phase , one year follow-up patient stimulator switch ON . There two differents group phase 3 : - Group A : 10 patient stimulator switch ON three month switch OFF next three month . - Group B : 10 patient opposite sequence , OFF ON . Main objective : - To show high frequency deep brain stimulation subthalamic nucleus decrease frequency epileptic seizure compare stimulation . Secondary objective : - To show high frequency deep brain stimulation subthalamic nucleus improve quality life . - To describe side effect device compare describe Parkinson patient . In particular check onset dyskinesia related dopamine . - To compare distribution seizure frequency stimulation base line . - To show number patient respond treatment high group stimulator switch ON group stimulator turn OFF . - To compare number day without seizure stimulator switch ON OFF . - To evaluate neuropsychologic effect induce neurostimulation - To quantify type ratio different seizure ON phase OFF phase . - To monitor secondary drug use study . Control visit : patient control visit every 4 week study .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Drug Resistant Epilepsy</mesh_term>
	<criteria>Epilepsy resistant antiepileptic drug dopaminergic D2 agonist . No curative exeresis surgery possible Metabolism deficiency DOPA 1 DS , evaluate Positron Emission Tomography ( PET ) use fluorodopa Age range 18 50 capacity consent Affiliation French Social Security pregnant woman nurse mother change antiepileptic , 30 day base line convulsive `` etat de mal '' require hospitalisation , 30 day base line</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>deep brain stimulation</keyword>
	<keyword>Subthalamic nucleus</keyword>
	<keyword>Drug resistant epilepsy</keyword>
</DOC>